(2021) A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. New Microbes New Infect. p. 100895. ISSN 2052-2975 (Print) 2052-2975
Full text not available from this repository.
Abstract
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized.
| Item Type: | Article |
|---|---|
| Keywords: | Covid-19 Hcv SARS-CoV-2 daclatasvir sofosbuvir |
| Page Range: | p. 100895 |
| Journal or Publication Title: | New Microbes New Infect |
| Journal Index: | Pubmed |
| Volume: | 42 |
| Identification Number: | https://doi.org/10.1016/j.nmni.2021.100895 |
| ISSN: | 2052-2975 (Print) 2052-2975 |
| Depositing User: | Zahra Otroj |
| URI: | http://eprints.mui.ac.ir/id/eprint/15158 |
Actions (login required)
 |
View Item |